Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male subjects.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02537405
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date February 2014
Completion date April 2014

See also
  Status Clinical Trial Phase
Completed NCT02537457 - Bioequivalence Study of Rivaroxaban Phase 1